Mankind Pharma faces Rs 183 crore tax demand, plans to appeal

Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, amounting to ₹183.11 crore, including interest. The demand arises from the disallowance of various expenditures under Section 37(1) of the Income-tax Act, 1961.

According to a regulatory filing, the orders were issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi.

The orders for AY 2014-15 and 2016-17 were dated March 24, 2025, while those for AY 2015-16 and 2017-18 were dated March 25, 2025. The company received the orders through the IT portal on March 28, 2025.

Mankind Pharma has said that it believes the tax demand is not legally justified and that it has strong factual and legal grounds to challenge the order. The company also asserted that the order is not expected to have any material impact on its financials or operations.

The pharmaceutical firm plans to appeal the order under applicable laws. Investors will be monitoring the situation closely as the company navigates this tax challenge.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states